Valiant LaboratoriesNSE:VALIANTLAB -0.06%51 Days Payable is 118.95 as of Mar. 2026, which is 75% above its 10-year median of 67.89. GuruFocus rates NSE:VALIANTLAB with a GF Score™ of 51/100 and a GF Value™ of ₹103.25 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 923 Drug Manufacturers companies, Valiant Laboratories ranks better than 62.95% on this metric.
The historical rank and industry rank for Valiant Laboratories's Days Payable or its related term are showing as below:
NSE:VALIANTLAB'
s Days Payable Range Over the Past 10 Years
Min: 36.19 Med: 67.89 Max: 124.72
Current: 113.07
During the past 6 years, Valiant Laboratories's highest Days Payable was 124.72. The lowest was 36.19. And the median was 67.89.
NSE:VALIANTLAB's Days Payable is ranked better than 62.95% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs NSE:VALIANTLAB: 113.07
Valiant Laboratories's Days Payable
increased
from Mar. 2025 (77.04) to Mar. 2026 (118.95).
It may suggest that Valiant Laboratoriesdelayed paying its suppliers.
Valiant Laboratories Days Payable Related Terms
Valiant Laboratories Days Payable Historical Data
* Premium members only.
The historical data trend for Valiant Laboratories's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valiant Laboratories Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's Days Payable distribution charts can be found below:
* The bar in red indicates where Valiant Laboratories's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Valiant Laboratories's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valiant Laboratories (NSE:VALIANTLAB) has a Days Payable of 118.95 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Valiant Laboratories and its competitors. This is 75% above median its historical median of 67.89. Over the past decade, Valiant Laboratories' Days Payable has ranged from 36.19 to 124.72. According to the industry distribution chart, Valiant Laboratories ranks #342 out of 923 companies in the Drug Manufacturers industry, placing it in the top 37.1%.
Is Valiant Laboratories' Days Payable too high?
Valiant Laboratories' current Days Payable of 118.95 is 75% above median its 10-year median of 67.89. Over the past 10 years, this metric has ranged from a low of 36.19 to a high of 124.72. The Drug Manufacturers industry median Days Payable is 90.98. Valiant Laboratories' value of 118.95 is 30.7% above this industry median. Based on the distribution chart, Valiant Laboratories ranks #342 out of 923 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Valiant Laboratories has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valiant Laboratories' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Valiant Laboratories ranks #342 out of 923 companies for Days Payable. This puts Valiant Laboratories in the upper half of its industry. The industry median Days Payable is 90.98. Valiant Laboratories' value of 118.95 is 30.7% above this benchmark. Historically, Valiant Laboratories' own Days Payable has ranged from 36.19 to 124.72 over the past decade. While the company's 10-year median is 67.89 vs. the industry median of 90.98, Valiant Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valiant Laboratories's current Days Payable of 118.95 is 30.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Valiant Laboratories and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valiant Laboratories's current Days Payable is 118.95, which is 75% above median its own 10-year median of 67.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valiant Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Valiant Laboratories (NSE:VALIANTLAB) is currently considered Possible Value Trap. The stock's GF Value™ is ₹103.25, compared to a current price of ₹68.00 — trading 34.1% below its estimated fair value. The current Days Payable is 118.95, which is 75% above median its 10-year median of 67.89 and 30.7% above the Drug Manufacturers industry median of 90.98. Valiant Laboratories' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Valiant Laboratories (NSE:VALIANTLAB), the current Days Payable is 118.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valiant Laboratories (NSE:VALIANTLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Valiant Laboratories stock appears to be undervalued.
The current stock price of ₹68.00 is trading 34.1% below its estimated GF Value™ of ₹103.25.
GuruFocus considers Valiant Laboratories to be Possible Value Trap.
Key valuation signals for NSE:VALIANTLAB:
Days Payable: 118.95 (75% above median its 10-year median of 67.89)
GF Value™: ₹103.25 vs. price of ₹68.00 (34.1% below fair value)
Industry Position: 30.7% above the Drug Manufacturers median (#342 of 923)
No single metric tells the full story. See the NSE:VALIANTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.
51GF Score
Get the complete analysis for NSE:VALIANTLAB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VALIANTLAB has been successfully added to your 
